Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance. 2003

M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
Department of Clinical and Experimental Medicine, Section of Microbiology, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy. mariacarla.re@unibo.it

Since the discovery of 3'-azido-3'deoxthymidine (zidovudine) as an effective antiretroviral agent against human immunodeficiency virus type 1 (HIV-1), drug therapy has been widely used in the treatment of AIDS. To date, new combination therapies have significantly altered the longterm prognosis for HIV-infected patients showing a reduction of plasma viral load, associated with clinical and immunological recovery. Nevertheless, in various circumstances treatment can fail for several reasons, such as patient noncompliance with the therapeutic regimen, suboptimal antiviral drug concentrations, drug pharmacokinetics, and virus resistance to one or more drugs. Virus drug resistance is the most important factor contributing to the failure of antiretroviral therapy. Since some evidence indicates that viral resistance and treatment failure are closely linked, this brief review explores the routine determination of drug resistance and its importance to shed more light on the meaning of mutations correlated to drug resistance.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
December 2002, Journal of medical virology,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
August 2007, Bulletin of mathematical biology,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
December 2009, Viruses,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
October 2014, Viruses,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
June 1994, Clinics in laboratory medicine,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
January 2020, Antiviral therapy,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
June 2013, Infectious disease reports,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
January 2017, Infection and drug resistance,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
April 2011, Infectious disorders drug targets,
M C Re, and I Bon, and P Monari, and R Gorini, and P Schiavone, and D Gibellini, and M La Placa
November 2016, The Journal of infectious diseases,
Copied contents to your clipboard!